# US 2025/0152560 A1 · Hdac inhibitor oki-179 in combination with binimetinib for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152560 A1
- Document ID: US20250152560A1
- Status: Published application
- Kind: A1
- Application number: 18/838,130
- Filed: 2023-02-13
- Published: 2025-05-15
- Earliest claimed: 2022-02-16
- Assignees: OnKure, Inc.; Array BioPharma Inc.
- Applicants: OnKure, Inc.; Array BioPharma Inc.
- Inventors: Anthony D. Piscopio; Patrice Anne Lee; James Winkler; Richard D. Woessner
- Web page: https://patentgrep.com/patent/US20250152560A1

## CPC

- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating cancer in a subject in need thereof, wherein the method comprises administration of therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, or administration of therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to the dosing schedules described herein.

## Claims

### Claim 1

A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-4 of the 7-day dosing cycle and binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle.

### Claim 2

A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-5 of the 7-day dosing cycle and binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle.

### Claim 3

A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-4 of the 7-day dosing cycle, binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle and encorafenib or a pharmaceutically acceptable salt thereof is administered once per day (QD) on days 1-7 of the 7-day dosing cycle.

### Claim 4

A method of treating cancer comprising administering to a subject in need thereof therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to a dosing schedule comprising at least one 7-day dosing cycle, wherein OKI-179 is administered once per day (QD) on days 1-5 of the 7-day dosing cycle, binimetinib or a pharmaceutically acceptable salt thereof is administered twice per day (BID) on days 1-7 of the 7-day dosing cycle and encorafenib or a pharmaceutically acceptable salt thereof is administered once per day (QD) on days 1-7 of the 7-day dosing cycle.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is a NRAS-mutated cancer or a BRAF-mutated cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein OKI-179 and binimetinib are administered within 30 minutes of each other.

### Claim 8 (depends on 3)

The method of claim 3, wherein OKI-179, binimetinib and encorafenib are administered within 30 minutes of each other.

### Claim 9 (depends on 1)

The method of claim 1, wherein OKI-179 and binimetinib are administered orally.

### Claim 10 (depends on 3)

The method of claim 3, wherein OKI-179, binimetinib and encorafenib are administered orally.

### Claim 11

A pharmaceutical combination comprising OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, and optionally encorafenib or a pharmaceutically acceptable salt thereof.

### Claim 12

(canceled)

### Claim 13 (depends on 2, 3)

The method of claim 2, wherein the cancer is a NRAS-mutated cancer or a BRAF-mutated cancer. 14 (New) The method of claim 3, wherein the cancer is a NRAS-mutated cancer or a BRAF-mutated cancer.

### Claim 15 (depends on 2, 4)

The method of claim 4, wherein the cancer is a NRAS-mutated cancer or a BRAF-mutated cancer. 16 (New) The method of claim 2, wherein OKI-179 and binimetinib are administered orally.

### Claim 17 (depends on 3)

The method of claim 3, wherein OKI-179 and binimetinib are administered orally.

### Claim 18 (depends on 4)

The method of claim 4, wherein OKI-179 and binimetinib are administered orally.

### Claim 19 (depends on 4)

The method of claim 4, wherein OKI-179, binimetinib and encorafenib are administered orally. Page 6

### Claim 20 (depends on 2)

The method of claim 2, wherein the subject is a human.

### Claim 21 (depends on 3)

The method of claim 3, wherein the subject is a human.

### Claim 22 (depends on 4)

The method of claim 4, wherein the subject is a human.
